 |
Oxfordshire Clinical Commissioning Group |
 |
Formulary |
|
Formulary Chapter 5: Infections - Full Section
|
Useful Links |
UKMI Q&A: Cross-sensitivity between penicillins and cephalosporins |
UKMI Q&A: Penicillins and cephalosporins safety in breast feeding |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
05.01 |
Antibacterial drugs
(0,2)
|
|

Table 1. Summary of antibacterial therapy
(0,0)
|
|

Table 2. Summary of antibacterial prophylaxis
(0,0)
|
05.01.01 |
Penicillins
(0,0)
|
05.01.01.01 |
Benzylpenicillin and phenoxymethylpenicillin
(4,0)
|
05.01.01.02 |
Penicillinase-resistant penicillins
(2,1)
|
05.01.01.03 |
Broad-spectrum penicillins
(4,2)
|
05.01.01.04 |
Antipseudomonal penicillins
(2,0)
|
05.01.01.05 |
Mecillinams
(2,0)
|
05.01.02 |
Cephalosporins, carbapenems and other beta-lactums
(2,0)
|
|

Cephalosporins
(0,4)
|
05.01.02.01 |
Cephalosporins
(8,3)
|
05.01.02.02 |
Carbapenems
(4,0)
|
05.01.02.03 |
Other beta-lactums antibiotics
(1,1)
|
05.01.03 |
Tetracyclines
(6,1)
|
|

Tigecycline
(1,0)
|
05.01.04 |
Aminoglycosides
(5,3)
|
05.01.05 |
Macrolides
(4,1)
|
05.01.06 |
Clindamycin
(2,0)
|
05.01.07 |
Some other antibacterials
(1,4)
|
|

Chloramphenicol
(1,0)
|
|

Fosfomycin
(1,0)
|
|

Fusidic acid
(1,0)
|
|

Vancomycin and teicoplanin
(3,1)
|
|

Daptomycin
(1,0)
|
|

Linezolid
(1,0)
|
|

Quinupristin and dalfopristin
(1,0)
|
|

Polymyxins
(1,0)
|
|

Rifaximin
(1,0)
|
|

Fidaxomicin
(1,0)
|
05.01.08 |
Sulphonamides and trimethoprim
(4,1)
|
05.01.09 |
Antituberculosis drugs
(16,1)
|
05.01.10 |
Antileprotic drugs
(2,0)
|
05.01.11 |
Metronidazole and tinidazole
(3,0)
|
05.01.12 |
Quinolones
(6,2)
|
05.01.13 |
Urinary-tract infections
(2,2)
|
05.02 |
Antifungal drugs
(12,1)
|
|

Treatment of fungal infections
(0,0)
|
|

Drugs used in fungal infections
(1,1)
|
05.02.01 |
Triazole antifungals
(0,0)
|
05.02.02 |
Imidazole antifungals
(0,0)
|
05.02.03 |
Polyene antifungals
(0,0)
|
05.02.04 |
Echinocandin antifungals
(1,2)
|
05.02.05 |
Other antifungals
(0,0)
|
05.03 |
Antiviral drugs
(1,1)
|
05.03.01 |
HIV infection
(0,2)
|
|

Nucleoside reverse transcriptase inhibitors
(19,2)
|
|

Protease inhibitors
(8,0)
|
|

Non-nucleoside reverse transcriptase inhibitors
(3,0)
|
|

Other antiretrovirals
(7,0)
|
|

Pharmacokinetic enhancers of anti-retrovirals
(0,0)
|
|

Combination Products
(0,0)
|
05.03.02 |
Herpesvirus infections
(0,1)
|
05.03.02.01 |
Herpes simplex and varicella-zoster infection
(3,1)
|
05.03.02.02 |
Cytomegalovirus infection
(4,1)
|
05.03.03 |
Viral hepatitis
(0,0)
|
05.03.03.01 |
Chronic hepatitis B
(2,2)
|
05.03.03.02 |
Chronic hepatitis C
(12,0)
|
05.03.04 |
Influenza
(3,1)
|
05.03.05 |
Respiratory syncytial virus
(4,0)
|
05.04 |
Antiprotozoal drugs
(0,0)
|
05.04.01 |
Antimalarials
(1,0)
|
|

Artemether with lumefabtrine
(1,0)
|
|

Chloroquine
(2,1)
|
|

Mefloquine
(1,0)
|
|

Primaquine
(1,0)
|
|

Proguanil
(2,2)
|
|

Pyrimethamine
(2,0)
|
|

Quinine
(1,0)
|
|

Tetracyclines
(0,1)
|
05.04.02 |
Amoebicides
(1,0)
|
05.04.03 |
Trichomonacides
(1,0)
|
05.04.04 |
Antigiardial drugs
(3,0)
|
05.04.05 |
Leishmaniacides
(1,0)
|
05.04.06 |
Trypanocides
(0,0)
|
05.04.07 |
Drugs for toxoplasmosis
(0,0)
|
05.04.08 |
Drugs for pneumocystis pneumonia
(2,1)
|
05.05 |
Anthelmintics
(0,0)
|
05.05.01 |
Drugs for threadworms
(3,0)
|
05.05.02 |
Ascaricides
(0,0)
|
05.05.03 |
Drugs for tapeworm infections
(0,1)
|
05.05.04 |
Drugs for hookworms
(0,0)
|
05.05.05 |
Schistosomicides
(1,0)
|
05.05.06 |
Filaricides
(0,0)
|
05.05.07 |
Drugs for cutaneous larva migrans
(1,0)
|
05.05.08 |
Drugs for strongyloidiasis
(0,0)
|
|
|
|